1
Home
Companies

Prothena

#7742

Rank

$334.8M

Marketcap

IE Ireland

Country

Prothena
Leadership team

Dr. Gene G. Kinney Ph.D. (Pres, CEO & Director)

Mr. Tran B. Nguyen M.B.A. (CFO & Chief Strategy Officer)

Mr. Brandon S. Smith (Chief Operating Officer)

Products/ Services
Biotechnology, Health Care, Health Diagnostics
Number of Employees
50 - 100
Headquarters
South San Francisco, California, United States
Established
2012
Company Registration
SEC CIK number: 0001559053
Revenue
5M - 20M
Traded as
PRTA
URL
https://www.prothena.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
History

Prothena was founded in 2012 by distinguished scientists, Kathy and Kevin Blucher, and was built upon a strong heritage of small and large molecule drug discovery and development activities. As a result, Prothena has achieved many important milestones over the past few years and is now a global, clinical-stage biotechnology company.

Mission
Prothena’s mission is to transform the treatment of disease by transforming the understanding of biological processes through innovative drug discovery and development.
Vision
Prothena's vision is to become the industry gold standard for how biology-based treatment of diseases is approached and advanced.
Key Team

Ms. Carol D. Karp (Chief Regulatory Officer)

Dr. Wagner M. Zago (Chief Scientific Officer)

Dr. Hideki Garren M.D., Ph.D. (Chief Medical Officer)

Ms. Jennifer Zibuda (Director of Investor Relations & Communication)

Ms. Karin L. Walker CPA, CPA (Chief Accounting Officer & Controller)

Mr. Michael J. Malecek (Chief Legal Officer)

Ms. Yvonne M. Tchrakian (Company Sec.)

Recognition and Awards
Prothena is the proud winner of several awards, such as the 2015 Frost & Sullivan Global Excellence Award for its achievements in the development of innovative product candidates targeting neurodegenerative diseases and the 2016 Global Outstanding Biomarkers Research Award by Bio-Strategy Partners.
References

https://in.investing.com/equities/prothena-corp

https://finance.yahoo.com/quote/PRTA/profile?p=PRTA

https://www.crunchbase.com/organization/prothena

https://sec.report/CIK/0001559053

https://companiesmarketcap.com/

https://www.prothena.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Prothena
Leadership team

Dr. Gene G. Kinney Ph.D. (Pres, CEO & Director)

Mr. Tran B. Nguyen M.B.A. (CFO & Chief Strategy Officer)

Mr. Brandon S. Smith (Chief Operating Officer)

Products/ Services
Biotechnology, Health Care, Health Diagnostics
Number of Employees
50 - 100
Headquarters
South San Francisco, California, United States
Established
2012
Company Registration
SEC CIK number: 0001559053
Revenue
5M - 20M
Traded as
PRTA
URL
https://www.prothena.com